Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833853 · ClinicalTrials.gov registry record
A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients
A clinical trial of Metastatic Breast Cancer (MBC), sponsored by Menarini Silicon Biosystems.
- Recruiting
- Registry status
- 187
- Enrollment target
- 1
- Study location
NCT06833853 is a study of Metastatic Breast Cancer (MBC) that is actively recruiting participants, run by Menarini Silicon Biosystems. The registered enrollment target is 187 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06833853, a study of Metastatic Breast Cancer (MBC), is actively recruiting participants, sponsored by Menarini Silicon Biosystems.
- RECRUITING
- Registry status
- 187 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Receptor 2 (HER2), Estrogen Receptor (ER), and programmed death-ligand 1 (PD-L1) and cell free DNA/RNA (cfDNA/RNA) analysis.
Conditions Studied
Study Locations (1)
Pennsylvania
- UPMC Magee Womens Hospital - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2026-03-13 |
| Est. Completion | 2028-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06833853
The ClinicalTrials.gov registry entry for NCT06833853 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Menarini Silicon Biosystems, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer (MBC) appearing as the primary indexed condition, and to 0 interventions.
NCT06833853 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06833853 about?
NCT06833853 is a clinical study titled "A Study for CTC Expression and cfDNA/RNA Assessment in Metastatic Breast Cancer Patients". The purpose of this research is to learn if the CellSearch Circulating Tumor Cells (CTC) test can help doctors in making decisions about treatment and monitoring of breast cancer. The test consists of diagnostic CTC counts (enumeration) and expression of biomarkers Human Epidermal growth factor Rece...
What is the current status of trial NCT06833853?
This trial is currently recruiting. The enrollment target is 187 participants. The study started on 2026-03-13. Estimated completion is 2028-10.
What conditions does trial NCT06833853 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer (MBC).
Who is sponsoring clinical trial NCT06833853?
This trial is sponsored by Menarini Silicon Biosystems, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06833853 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer (MBC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.